1. Home
  2. STRO vs JGH Comparison

STRO vs JGH Comparison

Compare STRO & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

N/A

Current Price

$8.76

Market Cap

159.5M

Sector

Health Care

ML Signal

N/A

Logo Nuveen Global High Income Fund of Beneficial Interest

JGH

Nuveen Global High Income Fund of Beneficial Interest

N/A

Current Price

$11.22

Market Cap

326.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
STRO
JGH
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
159.5M
326.0M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
STRO
JGH
Price
$8.76
$11.22
Analyst Decision
Strong Buy
Analyst Count
14
0
Target Price
★ $44.69
N/A
AVG Volume (30 Days)
★ 291.0K
79.6K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
★ 9.85%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $38,419,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.72
$11.20
52 Week High
$43.85
$13.00

Technical Indicators

Market Signals
Indicator
STRO
JGH
Relative Strength Index (RSI) 35.40 34.97
Support Level $8.11 N/A
Resistance Level $10.77 $12.90
Average True Range (ATR) 0.85 0.11
MACD 0.14 -0.02
Stochastic Oscillator 17.01 8.01

Price Performance

Historical Comparison
STRO
JGH

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About JGH Nuveen Global High Income Fund of Beneficial Interest

Nuveen Global High Income Fund operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The Fund's securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.

Share on Social Networks: